Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleix Prat

Showing results (1-10 of 326) with videos related to

Pageof 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Pertuzumab Use in the Adjuvant Setting: Why Not?Aleix Prat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapyAleix Prat, José Baselga
Medicina Clinica|August 3, 2007
[Biologic therapy: current and future applications in oncology]Aleix Prat, Josep Baselga
Breast (Edinburgh, Scotland)|August 15, 2021
Dissecting the biological heterogeneity of HER2-positive breast cancerFrancesco Schettini, Aleix Prat
Nature Clinical Practice. Oncology|July 9, 2008
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Aleix Prat, José Baselga
The Lancet. Oncology|November 5, 2020
Implementing preoperative endocrine therapy in breast cancerMontserrat Muñoz, Aleix Prat
Molecular Oncology|December 15, 2010
Deconstructing the molecular portraits of breast cancerAleix Prat, Charles M Perou
Molecular Oncology|May 8, 2010
WITHDRAWN: Deconstructing the molecular portraits of breast cancerAleix Prat, Charles M Perou
JCO Oncology Practice|June 2, 2021
Current and Future Management of HER2-Positive Metastatic Breast CancerOlga Martínez-Sáez, Aleix Prat
Journal of the National Cancer Institute|April 2, 2023
Reply to Bertucci, De Nonneville, and FinettiFara Brasó-Maristany, Aleix Prat
Pageof 33

Showing results (1-10 of 326) with videos related to

Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Pertuzumab Use in the Adjuvant Setting: Why Not?Aleix Prat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapyAleix Prat, José Baselga
Medicina Clinica|August 3, 2007
[Biologic therapy: current and future applications in oncology]Aleix Prat, Josep Baselga
Breast (Edinburgh, Scotland)|August 15, 2021
Dissecting the biological heterogeneity of HER2-positive breast cancerFrancesco Schettini, Aleix Prat
Nature Clinical Practice. Oncology|July 9, 2008
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Aleix Prat, José Baselga
The Lancet. Oncology|November 5, 2020
Implementing preoperative endocrine therapy in breast cancerMontserrat Muñoz, Aleix Prat
Molecular Oncology|December 15, 2010
Deconstructing the molecular portraits of breast cancerAleix Prat, Charles M Perou
Molecular Oncology|May 8, 2010
WITHDRAWN: Deconstructing the molecular portraits of breast cancerAleix Prat, Charles M Perou
JCO Oncology Practice|June 2, 2021
Current and Future Management of HER2-Positive Metastatic Breast CancerOlga Martínez-Sáez, Aleix Prat
Journal of the National Cancer Institute|April 2, 2023
Reply to Bertucci, De Nonneville, and FinettiFara Brasó-Maristany, Aleix Prat
Pageof 33